Efficacy of doxorubicin thermosensitive liposomes (40° C) and local hyperthermia on rat rhabdomyosarcoma

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 365-372

  Morita, Kotaro ^a   Zywietz, Friedrich ^b   Kakinuma, Kenichi ^a   Tanaka, Ryuichi ^a   Katoh, Masashi ^c  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

Doxorubicin; Local hyperthermia; Rat rhabdomyosarcoma; Thermosensitive liposomes

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG UPTAKE; HEART; HYPERTHERMIC THERAPY; INFRARED RADIATION; KIDNEY; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; SPLEEN; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG CARRIERS; HYPERTHERMIA, INDUCED; LIPOSOMES; MALE; RATS; RATS, INBRED STRAINS; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE;

EID: 48749113757     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000016     Document Type: Article

References (58)

1. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271: 58-65, 1994.
2. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95-105, 1988.
3. Yuan F: Transvascular drug delivery in solid tumors. Sem Radiat Oncol 8: 164-175, 1998.
4. Molls M and Vaupel P (eds): Blood Perfusion and Microenvironment of Human Tumors. Springer, Berlin, pp1-238, 1998.
5. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR and Dewhirst MW: Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 53: 3765-3770, 1993.
6. Allen TM: Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15: 215-220, 1994.
7. Massing U: Cancer therapy with liposomal formulations of anticancer drugs. Int J Clin Pharmacol Ther 35: 87-90, 1997.
8. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS and Bally MB: Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22: 225-250, 2002.
9. Allen TM and Cullis PR: Drug delivery systems: entry the mainstream. Science 303: 1818-1822, 2004.
10. Garcia AA, Kempf RA, Rogers M and Muggia FM: A Phase II study of doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 9: 1131-1133, 1998.
11. Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O and Legha SS: Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 6: 1097-1099, 1999.
12. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S. Steinbrecher A, Ullrich W and Bogdahn U: Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92: 1936-1942, 2001.
13. Muggia F and Hamilton A: Phase III data on caelix in ovarian cancer. Eur J Cancer 37: 15-18, 2001.
14. Judson I, Radford JA, Harris M, et al: Randomized phase II trial of pegylated liposomal doxorubicin (Doxil/Caelix) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group. Eur J Cancer 37: 870-877, 2001.
15. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L and Winer E: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94: 25-36, 2002.
16. Yatvin MB, Weinstein JN, Dennis WH and Blumenthal R: Design of liposomes for enhanced release of drugs by hyperthermia. Science 202: 1290-1293, 1978.
17. Weinstein JN, Magin RL, Yatvin MB and Zaharko DS: Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 204: 188-191, 1979.
18. Weinstein JN, Magin RL, Cysyk RL and Zaharko DS: Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate. Cancer Res 40: 3748-3755, 1980.
19. Kong G and Dewhirst MW: Hyperthermia and liposomes: a review. Int J Hyperthermia 15: 345-370, 1999.
20. Needham D and Dewhirst MW: The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 53: 285-305, 2001.
21. Kono K and Takagishi T: Temperature-sensitive liposomes. Methods Enzymol 387: 73-82, 2004.
22. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD and Dellian M: Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 10: 2168-2178, 2004.
23. Han HD, Shin BC and Choi HS: Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropyl-acrylamide-co-acrylamide): drug release behavior and stability in the presence of serum. Eur J Pharm Biopharm 62: 110-116, 2006.
24. Ponce AM, Vujaskovic Z, Yuan F, Needham D and Dewhirst MW: Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia 22: 205-213, 2006.
25. Unezaki S, Maruyama K, Takahashi N, Koyama M, Yuda T, Suginaka A and Iwatsuru M: Enhanced delivery and tumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res 11: 1180-1185, 1994.
26. Huang SK, Stauffer PR, Hong K, Guo JW, Philips TL, Huang A and Papahadjopoulos D: Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin sterically stabilized liposomes. Cancer Res 54: 2186-2191, 1994.
27. Kakinuma K, Tanaka R, Takahashi H, Watanabe M, Nakagawa T and Kuroki M: Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J Neurosurg 84: 180-184, 1996.
28. Needham D, Anyarambhatla G, Kong G and Dewhirst MW: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60: 1197-1201, 2000.
29. Kong G, Anayarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D and Dewhirst MW: Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60: 6950-6957, 2000.
30. Matteucci ML, Anayarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D and Thrall DE: Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 6: 3748-3755, 2000.
31. Ishida O, Maruyama K, Yanagie H, Eriguchi M and Iwatsuru M: Targeting chemotherapy to solid tumors with long-circulating thermosensitive liposomes and local hyperthermia. Jpn J Cancer Res 91: 118-126, 2000.
32. Shimose S, Sugita T, Nitta Y, Kubo T, Ikuta Y and Murakami T: Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma. Int J Oncol 19: 585-589, 2001.
33. Aoki H, Kakinuma K, Morita K, Kato M, Uzuka T, Igor G, Takahashi H and Tanaka R: Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposomes: evaluation of drug distribution in a rat glioma model. Int J Hyperthermia 20: 595-605, 2004.
34. Hauck ML, LaRue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, Pruitt AF, Klein A, Case B, Thrall DE, Needham D and Dewhirst MW: Phase I trial of doxorubicin - containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 12: 4004-4010, 2006.
35. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB and Dewhirst MW: In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med Sci 51: 1153-1162, 2004.
36. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB and Dewhirst MW: Magnetic resonance imaging of temperature sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 99: 53-63, 2007.
37. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW and Papahadjopoulos D: Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 36: 1177-1187, 1996.
38. Kong G, Braun RD and Dewhirst MW: Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 60: 4440-4445, 2000.
39. Kong G, Braun RD and Dewhirst MW: Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 61: 3027-3032, 2001.
40. Demetri GD and Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin North Am 9: 765-785, 1995.
41. Zywietz F, Böhm L, Sagowski C and Kehrl W: Pentoxifylline enhances tumor oxygenation in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol 180: 306-314, 2004.
42. Zywietz F: Biological aspects of applying hyperthermia to radiation. In: Advances in Hyperthermic Oncology. Tanaka R (ed). Koko-Do Co., Niigata, pp10-15, 2001.
43. Thews O, Zywietz F, Lecher B and Vaupel P: Quantitative changes of metabolic and bioenergetic parameters in experimental tumors during fractionated irradiation. Int J Radiat Oncol Biol Phys 45: 1281-1288, 1999.
44. Tilki D, Kilic N, Sevinc S, Zywietz F, Stief CG and Ergün S: Zone-specific remodeling of tumor blood vessels affects tumor growth. Cancer 110: 2347-2362, 2007.
45. 2) in a rat rhabdomyosarcoma: a methodical study. In: Tumor Oxygenation. Vaupel PW, Kelleher DK, Günderoth M (eds). G. Fischer Verlag, Stuttgart, pp59-72, 1995.
46. Zywietz F: Simultaneous treatment of an experimental tumor with fractionated radiation and infrared-A-hyperthermia. Indian J Exp Biol 34: 833-837, 1996.
47. Kelleher DK, Engel T and Vaupel PW: Changes in micro-regional perfusion, oxygenation, ATP and lactate distribution in subcutaneous rat tumors upon water-filtered IR-A-hyperthermia. Int J Hyperthermia 11: 241-255, 1995.
48. Morita K, Tanaka R, Kakinuma K, Takahashi H and Motoyama H: Combination therapy of rat brain tumors using localized interstitial hyperthermia and intra-arterial chemotherapy. Int J Hyperthermia 19: 204-212, 2003.
49. Chen Q, Tong S, Dewhirst MW and Yuan F: Targeting tumor microvessels using doxorubicin encapsulated in novel thermosensitive liposome. Mol Cancer Ther 3: 1311-1317, 2004.
50. Reinhold HS and van den Berg-Block: Differences in the response of the microcirculation to hyperthermia in five different tumors. Eur J Cancer Clin Oncol 25: 611-618, 1989.
51. Song CW, Park HJ, Lee CK and Griffin R: Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 21: 761-767, 2005.
52. Liu P, Zhang A, Xu Y and Xu LX: Study of non-uniform nanoparticle liposome extravasation in tumor. Int J Hyperthermia 21: 259-270, 2005.
53. Lorke DE, Wenzel S, Siebert K and Zywietz F: Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: an electron microscopic investigation on the rat R1H rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 44: 895-904, 1999.
54. Kehrl W, Sagowski C, Wenzel S and Zywietz F: Oxygenation of tumor recurrences following fractionated radiotherapy of primary tumors. Studies on the rhabdomyosarcoma R1H of the rat. Strahlenther Onkol 180: 383-390, 2004.
55. Alberts DS and Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54: 30-35, 1997.
56. van Bree C, Krooshoop JJ, Rietbroek RC, Kipp JB and Bakker PJ: Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res 56: 563-568, 1996.
57. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH and Storm G: Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injections. J Pharmacol Exp Ther 298: 607-612, 2001.
58. Laverman P, Boerman OC, Oyen WJG, Corstens FHM and Storm C: In vivo application of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst 18: 551-566, 2001.